BioLife Solutions, Inc. reported a total revenue of $96.2 million for the fiscal year ended December 31, 2025, marking a 29% increase from $74.6 million in 2024. This growth was primarily driven by a 30% rise in sales of biopreservation media products, attributed to increased demand from customers with commercially approved therapies. The company's gross profit also rose to $62.1 million, resulting in a gross margin of 65%, slightly down from 67% in the previous year due to higher costs of materials and a less favorable product mix.
In terms of operational changes, BioLife made significant strategic moves, including the acquisition of the remaining 90% of PanTHERA CryoSolutions, which is expected to enhance its capabilities in biopreservation technology. The company also divested several businesses, including SAVSU, CBS, SciSafe, and Global Cooling, to streamline its focus on higher-margin products. The divestiture of SAVSU, completed in October 2025, resulted in a gain of $10.3 million, while the divestitures of CBS and SciSafe in late 2024 also contributed to the company's financial restructuring.
The company’s workforce consisted of 155 full-time employees as of December 31, 2025, reflecting a commitment to maintaining a skilled team amid ongoing operational changes. BioLife's customer base remains concentrated, with three customers accounting for approximately 29% of total revenue in 2025. The company continues to focus on expanding its geographic reach, with 80% of revenue generated from the United States, while the Europe, Middle East, and Africa (EMEA) region contributed 14%.
Looking ahead, BioLife Solutions anticipates continued growth driven by the expanding cell and gene therapy market, which is projected to generate significant revenue in the coming years. The company is committed to enhancing its product offerings and operational efficiencies while navigating potential challenges such as supply chain disruptions and regulatory changes. The management remains optimistic about leveraging its recent acquisitions and divestitures to strengthen its market position and drive future profitability.
About BIOLIFE SOLUTIONS INC
BioLife Solutions, Inc. develops and manufactures bioproduction products and services that support cell and gene therapy (CGT) manufacturing and distribution. Its portfolio includes proprietary biopreservation media, cell processing tools, automated thawing devices, and cloud-connected cold chain shipping containers. Serving biopharma and research customers globally, BioLife’s products enhance biologic material viability, extend shelf-life, and improve process consistency, leveraging cGMP manufacturing and scientific expertise to reduce risks in CGT workflows.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.